Strides Pharma Science Management

Management criteria checks 2/4

Strides Pharma Science's CEO is Arun Pillai, appointed in Apr 2022, has a tenure of 2.08 years. total yearly compensation is ₹60.00M, comprised of 0% salary and 100% bonuses, including company stock and options. directly owns 2.11% of the company’s shares, worth ₹1.74B. The average tenure of the management team and the board of directors is 4.7 years and 8.4 years respectively.

Key information

Arun Pillai

Chief executive officer

₹60.0m

Total compensation

CEO salary percentage	0.0%
CEO tenure	2.1yrs
CEO ownership	2.1%
Management average tenure	4.7yrs
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Arun Pillai's remuneration changed compared to Strides Pharma Science's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-₹2b
Sep 30 2023	n/a	n/a	-₹2b
Jun 30 2023	n/a	n/a	-₹924m
Mar 31 2023	₹60m	₹1	-₹2b
Dec 31 2022	n/a	n/a	-₹2b
Sep 30 2022	n/a	n/a	-₹2b
Jun 30 2022	n/a	n/a	-₹4b
Mar 31 2022	₹800k	n/a	-₹5b
Dec 31 2021	n/a	n/a	-₹4b
Sep 30 2021	n/a	n/a	-₹3b
Jun 30 2021	n/a	n/a	-₹543m
Mar 31 2021	₹8m	n/a	₹3b
Dec 31 2020	n/a	n/a	₹28m
Sep 30 2020	n/a	n/a	₹589m
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹72m	₹49m	₹492m
Dec 31 2019	n/a	n/a	₹3b
Sep 30 2019	n/a	n/a	₹2b
Jun 30 2019	n/a	n/a	₹745m
Mar 31 2019	₹50m	₹38m	₹840m
Dec 31 2018	n/a	n/a	-₹93m
Sep 30 2018	n/a	n/a	₹139m
Jun 30 2018	n/a	n/a	₹415m
Mar 31 2018	₹106m	₹14m	₹544m

Compensation vs Market: Arun's total compensation ($USD719.04K) is above average for companies of similar size in the Indian market ($USD380.97K).

Compensation vs Earnings: Arun's compensation has increased whilst the company is unprofitable.

CEO

Arun Pillai (62 yo)

2.1yrs

Tenure

₹60,000,001

Compensation

Mr. Arun Kumar Pillai, B.Com., is Founder of Solara Active Pharma Sciences Limited and serves as its Non-Executive Director since August 04, 2021 and its Founder. Mr. Pillai has been Executive Chairperson...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Arun Pillai	Founder	2.1yrs	₹60.00m	2.11% ₹ 1.7b
Badree Komandur	Group CFO	10.8yrs	₹44.00m	0.027% ₹ 22.4m
Manjula Ramamurthy	Compliance Officer & Company Secretary	7.3yrs	₹5.86m	no data
P. V. Ramaraju	Chief Operating Officer	less than a year	no data	no data
Sormistha Ghosh	Group General Counsel & Chief Risk Officer	no data	no data	no data
C. Sundar	Executive Vice President of Operations	no data	no data	no data
Kevin Cook	Senior Vice President of Strides Pharma Inc.	no data	no data	no data
Umesh Kale	Chief Quality Officer	no data	no data	no data
A. Narayanan	Chief Information Technology Officer	no data	no data	no data
Vinod Nair	Senior Vice President of Institutional Business	no data	no data	no data
Amol Mehta	Senior Vice President of Regulated Markets	no data	no data	no data
Amit Gupta	Senior Vice President of Taxation	no data	no data	no data

4.7yrs

Average Tenure

Experienced Management: 532531's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Arun Pillai	Founder	33.9yrs	₹60.00m	2.11% ₹ 1.7b
Badree Komandur	Group CFO	7yrs	₹44.00m	0.027% ₹ 22.4m
Homi Khusrokhan	Independent Director	7yrs	₹2.20m	no data
Srinivasan Sridhar	Independent Director	11.8yrs	₹2.20m	no data
Dennis Bastas	Executive Chairman of Arrow Pharmaceuticals Pty Ltd	no data	no data	no data
Gopakumar Nair	Member of Scientific Advisory Board	no data	no data	no data
Elias Neto	Member of Scientific Advisory Board	no data	no data	no data
S. Vyas	Member of Scientific Advisory Board	no data	no data	no data
B. Suresh	Member of Scientific Advisory Board	no data	no data	no data
C. Gupta	Member of Scientific Advisory Board	no data	no data	no data
Bharat Shah	Independent Director	9.8yrs	₹2.20m	0.083% ₹ 68.5m
Kausalya Santhanam	Independent Director	4.4yrs	₹2.20m	0.0013% ₹ 1.1m

8.4yrs

Average Tenure

72yo

Average Age

Experienced Board: 532531's board of directors are considered experienced (8.4 years average tenure).

Strides Pharma Science Management

Management criteria checks 2/4

Key information

Recent management updates

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Strides Pharma Science Limited Announces Change in Management

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Recent updates

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Price target increased by 10% to ₹730

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

First quarter 2024 earnings released: ₹0.79 loss per share (vs ₹15.13 loss in 1Q 2023)

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Executive Changes

Founder & Non-Executive Chairman recently bought ₹50m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP

Price target decreased to ₹735

Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021)

Insider recently sold ₹1.5m worth of stock

Price target decreased to ₹857

Insider recently sold ₹14m worth of stock

First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021)

Less than half of directors are independent

Upcoming dividend of ₹2.50 per share

Insider recently sold ₹2.8m worth of stock

Chief Human Resource Officer recently sold ₹4.1m worth of stock

Full year 2021 earnings released: EPS ₹28.40 (vs ₹5.49 in FY 2020)

TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India

Third quarter 2021 earnings released: EPS ₹4.22 (vs ₹10.48 in 3Q 2020)

Price target raised to ₹886

Revenue and earnings miss expectations

Strides Pharma Science Limited to Report Q3, 2021 Results on Feb 04, 2021

Aditya Puri Joins as Advisor to the Strides Group

Strides Pharma Reportedly May Get Transferred to A Clutch of Investors as Promoters Plan to Exit

New 90-day high: ₹901

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹3.1m worth of stock

New 90-day high: ₹764

Second-quarter earnings released: Revenue misses expectations

First half earnings released

Price target raised to ₹786

New 90-day high: ₹729

Pronomz Ventures LLP completed the acquisition of 3.7% stake in Strides Pharma Science Limited (NSEI:STAR) from Sequent Scientific Limited (BSE:512529)

Price target raised to ₹703